本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Purple Biotech Ltd.

4.10
+0.26006.77%
盤後4.100.00000.00%19:02 EDT
成交量:1.51萬
成交額:5.93萬
市值:370.25萬
市盈率:-0.38
高:4.13
開:3.83
低:3.70
收:3.84
52周最高:30.50
52周最低:3.70
股本:90.30萬
流通股本:83.58萬
量比:1.12
換手率:1.81%
股息:- -
股息率:- -
每股收益(TTM):-10.8400
每股收益(LYR):-44.1580
淨資產收益率:-10.48%
總資產收益率:-8.48%
市淨率:0.11
市盈率(LYR):-0.09

資料載入中...

2025/08/30

SEC問詢函

Form CORRESP - Correspondence
2025/08/30

SEC問詢函

Form CORRESP - Correspondence
2025/08/29

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2025/03/10

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/15

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/07/27

SEC問詢函

Form CORRESP - Correspondence
2024/07/22

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2024/03/05

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/14

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/11/14

SEC問詢函

Form CORRESP - Correspondence
2023/11/14

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2023/10/31

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2023/05/18

SEC問詢函

Form CORRESP - Correspondence
2023/04/03

SEC問詢函

CORRESP [Cover] - Correspondence
2023/03/03

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/04/04

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/03/09

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/04/09

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/03/16

[修訂]年度報告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/16

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]